NIPSNAP2
gene geneOn this page
Summary
NIPSNAP2 (nipsnap homolog 2, HGNC:4179) is a protein-coding gene on chromosome 7p11.2, encoding Protein NipSnap homolog 2 (O75323). Protein involved in mitophagy by facilitating recruitment of the autophagy machinery required for clearance of damaged mitochondria.
This gene encodes a member of the NipSnap family of proteins that may be involved in vesicular transport. The encoded protein is localized to mitochondria and plays a role in oxidative phosphorylation. A pseudogene of this gene is located on the long arm of chromosome 2. Alternatively spliced transcript variants encoding multiple isoforms have been observed for this gene.
Source: NCBI Gene 2631 — RefSeq curated summary.
At a glance
- GWAS associations: 10
- Clinical variants (ClinVar): 70 total
- MANE Select transcript:
NM_001483
Identifiers
Gene identifiers
| Field | Value |
|---|---|
| HGNC ID | HGNC:4179 |
| Approved symbol | NIPSNAP2 |
| Name | nipsnap homolog 2 |
| Location | 7p11.2 |
| Locus type | gene with protein product |
| Status | Approved |
| Ensembl gene | ENSG00000146729 |
| Ensembl biotype | protein_coding |
| OMIM | 603004 |
| Entrez | 2631 |
Gene structure
Transcript identifiers
Ensembl transcripts: 21 — 14 protein_coding, 3 retained_intron, 2 nonsense_mediated_decay, 2 protein_coding_CDS_not_defined
ENST00000322090, ENST00000415967, ENST00000437587, ENST00000446692, ENST00000446778, ENST00000456204, ENST00000464772, ENST00000470036, ENST00000472404, ENST00000487370, ENST00000497279, ENST00000878200, ENST00000878201, ENST00000878202, ENST00000878203, ENST00000878204, ENST00000878205, ENST00000878206, ENST00000878207, ENST00000942464, ENST00000942465
RefSeq mRNA: 2 — MANE Select: NM_001483
NM_001202469, NM_001483
CCDS: CCDS5521, CCDS56488
Canonical transcript exons
ENST00000322090 — 10 exons
| Exon | Start | End |
|---|---|---|
| ENSE00003463226 | 55982210 | 55982280 |
| ENSE00003473689 | 55978126 | 55978265 |
| ENSE00003567758 | 55997366 | 55997449 |
| ENSE00003569823 | 55978350 | 55978395 |
| ENSE00003600824 | 55983728 | 55983868 |
| ENSE00003653217 | 55981473 | 55981567 |
| ENSE00003690724 | 55994894 | 55994988 |
| ENSE00003694101 | 55984847 | 55984878 |
| ENSE00003842344 | 55964585 | 55964701 |
| ENSE00003843507 | 55999008 | 56000179 |
Expression profiles
Bgee: expression breadth ubiquitous, 291 present calls, max score 99.64.
FANTOM5 (CAGE): breadth ubiquitous, TPM avg 54.6305 / max 1009.6659, expressed in 1822 samples.
FANTOM5 promoters (3 alternative TSS)
| Promoter ID | TPM avg | Samples expressed |
|---|---|---|
| 78765 | 53.2139 | 1821 |
| 78767 | 1.1669 | 622 |
| 78766 | 0.2496 | 82 |
Top tissues by expression
295 total, by Bgee expression score (0-100, higher = more expressed):
| Tissue | Anatomy ID | Expression score | Quality |
|---|---|---|---|
| biceps brachii | UBERON:0001507 | 99.64 | gold quality |
| skeletal muscle tissue of biceps brachii | UBERON:0004502 | 99.57 | gold quality |
| vastus lateralis | UBERON:0001379 | 99.47 | gold quality |
| quadriceps femoris | UBERON:0001377 | 99.38 | gold quality |
| heart right ventricle | UBERON:0002080 | 99.37 | gold quality |
| skeletal muscle tissue of rectus abdominis | UBERON:0004511 | 99.32 | gold quality |
| diaphragm | UBERON:0001103 | 99.12 | gold quality |
| skeletal muscle tissue | UBERON:0001134 | 99.08 | gold quality |
| muscle organ | UBERON:0001630 | 99.04 | gold quality |
| gastrocnemius | UBERON:0001388 | 99.02 | gold quality |
| deltoid | UBERON:0001476 | 98.96 | gold quality |
| muscle of leg | UBERON:0001383 | 98.95 | gold quality |
| hindlimb stylopod muscle | UBERON:0004252 | 98.94 | gold quality |
| triceps brachii | UBERON:0001509 | 98.82 | gold quality |
| body of tongue | UBERON:0011876 | 98.79 | gold quality |
| myocardium | UBERON:0002349 | 98.64 | gold quality |
| muscle tissue | UBERON:0002385 | 98.63 | gold quality |
| gluteal muscle | UBERON:0002000 | 98.52 | gold quality |
| tibialis anterior | UBERON:0001385 | 98.32 | gold quality |
| left ventricle myocardium | UBERON:0006566 | 98.32 | gold quality |
| bronchial epithelial cell | CL:0002328 | 98.16 | gold quality |
| cardiac ventricle | UBERON:0002082 | 98.15 | gold quality |
| heart left ventricle | UBERON:0002084 | 98.13 | gold quality |
| cardiac muscle of right atrium | UBERON:0003379 | 98.04 | gold quality |
| cardiac atrium | UBERON:0002081 | 97.81 | gold quality |
| right atrium auricular region | UBERON:0006631 | 97.78 | gold quality |
| apex of heart | UBERON:0002098 | 97.46 | gold quality |
| heart | UBERON:0000948 | 97.41 | gold quality |
| olfactory segment of nasal mucosa | UBERON:0005386 | 96.71 | gold quality |
| pigmented layer of retina | UBERON:0001782 | 96.67 | gold quality |
Single-cell (SCXA)
Detected in 1 experiment(s), a significant marker in 1.
| Experiment | Marker? | Max mean expression |
|---|---|---|
| E-ANND-3 | yes | 14.34 |
Regulation
Is transcription factor: no
Upstream regulators (CollecTRI, top): ESR2
miRNA regulators (miRDB)
66 targeting NIPSNAP2, top 30 by miRDB confidence (max_score; target_count = how many genes the miRNA targets in total — lower means more specific):
| miRNA | Max score | Avg score | miRNA target_count |
|---|---|---|---|
| HSA-MIR-5193 | 100.00 | 67.26 | 1744 |
| HSA-MIR-4262 | 100.00 | 73.26 | 3931 |
| HSA-MIR-548C-3P | 99.99 | 74.01 | 7587 |
| HSA-MIR-4789-3P | 99.99 | 70.75 | 2484 |
| HSA-MIR-607 | 99.97 | 73.62 | 5593 |
| HSA-MIR-590-3P | 99.96 | 74.34 | 6478 |
| HSA-MIR-23A-3P | 99.95 | 74.24 | 3163 |
| HSA-MIR-23B-3P | 99.95 | 74.24 | 3163 |
| HSA-MIR-23C | 99.95 | 73.92 | 3192 |
| HSA-MIR-8063 | 99.91 | 69.76 | 3146 |
| HSA-MIR-627-3P | 99.90 | 71.42 | 3316 |
| HSA-MIR-3151-5P | 99.86 | 63.83 | 1069 |
| HSA-MIR-5010-3P | 99.83 | 70.60 | 2357 |
| HSA-MIR-4495 | 99.82 | 72.08 | 3080 |
| HSA-MIR-6875-3P | 99.82 | 70.26 | 2983 |
| HSA-MIR-370-5P | 99.78 | 66.81 | 706 |
| HSA-MIR-4679 | 99.76 | 69.19 | 1229 |
| HSA-MIR-498-5P | 99.76 | 69.64 | 1807 |
| HSA-MIR-4719 | 99.73 | 72.10 | 3329 |
| HSA-MIR-132-3P | 99.73 | 70.56 | 1424 |
| HSA-MIR-212-3P | 99.73 | 70.65 | 1424 |
| HSA-MIR-1200 | 99.71 | 70.42 | 1838 |
| HSA-MIR-4677-5P | 99.70 | 70.09 | 1940 |
| HSA-MIR-494-3P | 99.70 | 71.45 | 2795 |
| HSA-MIR-466 | 99.67 | 70.85 | 2863 |
| HSA-MIR-378A-5P | 99.65 | 66.33 | 1311 |
| HSA-MIR-24-3P | 99.59 | 69.97 | 1934 |
| HSA-MIR-1290 | 99.59 | 69.90 | 2079 |
| HSA-MIR-12122 | 99.56 | 69.33 | 1672 |
| HSA-MIR-7159-3P | 99.51 | 70.17 | 1920 |
Literature-anchored findings (GeneRIF, showing 7)
- CHCHD10 and GBAS are involved in oxidative phosphorylation. (PMID:20888800)
- GBAS mutations could not explain phenotype of patients with combined oxidative phosphorylation system deficiencies. (PMID:24137763)
- identified mitochondrial proteins 4-nitrophenylphosphatase domain and non-neuronal synaptosomal associated protein 25-like protein homolog (NIP-SNAP)-1 and -2 as clarithromycin-binding proteins. Production of proinflammatory cytokines induced by lipopolysaccharides and Pam3-CSK4 in epithelial cell lines BEAS-2B and T24 were suppressed by knockdown of NIP-SNAP-1 or -2 (PMID:27998764)
- NIP-SNAP-1 and -2 localized in the mitochondrial inner membrane space, whereas HSP60 localized in the matrix. Expression levels of NIP-SNAP-1 and -2 in cells were decreased by knockdown of HSP60, but not HSP10. The findings indicate that HSP60 promotes folding and maintains the stability of NIP-SNAP-1 and -2. (PMID:28011268)
- Results show that the rs9642391C>G variant, which is located in the intron region of EGFR, is associated with GBAS expression and survival outcomes in surgically resected early-stage non-small cell lung cancer patients. (PMID:29806744)
- NIPSNAP1 and NIPSNAP2 have a redundant function in mitophagy and are predominantly expressed in different tissues. (PMID:30982665)
- Knockdown of GBAS regulates esophageal cancer cell viability and apoptosis. (PMID:34036378)
Cross-species orthologs
5 orthologs
| Organism | Symbol | Gene ID |
|---|---|---|
| danio_rerio | nipsnap2 | ENSDARG00000007264 |
| mus_musculus | Nipsnap2 | ENSMUSG00000029432 |
| rattus_norvegicus | Nipsnap2 | ENSRNOG00000023919 |
| drosophila_melanogaster | Nipsnap | FBGN0030724 |
| caenorhabditis_elegans | WBGENE00019301 |
Paralogs (3): NIPSNAP3A (ENSG00000136783), NIPSNAP3B (ENSG00000165028), NIPSNAP1 (ENSG00000184117)
Protein
Protein identifiers
Protein NipSnap homolog 2 — O75323 (reviewed: O75323)
Alternative names: Glioblastoma-amplified sequence
All UniProt accessions (5): O75323, C9J7B1, C9K068, F8WBI5, H7C333
UniProt curated annotations — full annotation on UniProt →
Function. Protein involved in mitophagy by facilitating recruitment of the autophagy machinery required for clearance of damaged mitochondria. Accumulates on the mitochondria surface in response to mitochondrial depolarization and acts as a ’eat me’ signal by recruiting proteins involved in selective autophagy, such as autophagy receptors (CALCOCO2/NDP52, NBR1, SQSTM1/p62, TAX1BP1 and WDFY3/ALFY) and ATG8 family proteins (MAP1LC3A, MAP1LC3B, MAP1LC3C, GABARAP, GABARAPL1 and GABARAPL2).
Subunit / interactions. Interacts with CALCOCO2/NDP52, NBR1, SQSTM1/p62, TAX1BP1 and WDFY3/ALFY. Interacts with ATG8 family proteins (MAP1LC3A, MAP1LC3B, MAP1LC3C, GABARAP, GABARAPL1 and GABARAPL2). Interacts with VDAC1.
Subcellular location. Mitochondrion matrix.
Tissue specificity. Widely expressed. Most abundant in heart and skeletal muscle.
Similarity. Belongs to the NipSnap family.
Isoforms (2)
| UniProt ID | Names | Canonical? |
|---|---|---|
| O75323-1 | 1 | yes |
| O75323-2 | 2 |
RefSeq proteins (2): NP_001189398, NP_001474* (*=MANE)
Domains & families (InterPro)
| ID | Name | Type |
|---|---|---|
| IPR011008 | Dimeric_a/b-barrel | Homologous_superfamily |
| IPR012577 | NIPSNAP | Domain |
| IPR051557 | NipSnap_domain | Family |
Pfam: PF07978
UniProt features (4 total): transit peptide 1, chain 1, splice variant 1, sequence conflict 1
Structure
Experimental structures (PDB)
0 structures.
Predicted structure (AlphaFold)
| Model | pLDDT | Fraction very-high |
|---|---|---|
| AF-O75323-F1 | 84.14 | 0.73 |
Function
Pathways and Gene Ontology
Reactome pathways
2 pathways
| ID | Pathway |
|---|---|
| R-HSA-9013407 | RHOH GTPase cycle |
| R-HSA-9013409 | RHOJ GTPase cycle |
MSigDB gene sets: 160 (showing top):
GOBP_POSITIVE_REGULATION_OF_CATION_CHANNEL_ACTIVITY, GOBP_POSITIVE_REGULATION_OF_TRANSPORTER_ACTIVITY, GOBP_REGULATION_OF_VOLTAGE_GATED_CALCIUM_CHANNEL_ACTIVITY, TGACCTY_ERR1_Q2, GOBP_POSITIVE_REGULATION_OF_TRANSMEMBRANE_TRANSPORT, GOBP_MONOATOMIC_CATION_TRANSPORT, GOBP_MACROAUTOPHAGY, GOBP_POSITIVE_REGULATION_OF_MOLECULAR_FUNCTION, MILI_PSEUDOPODIA_HAPTOTAXIS_UP, GOBP_POSITIVE_REGULATION_OF_MONOATOMIC_ION_TRANSPORT, GENTILE_UV_HIGH_DOSE_DN, GOCC_MITOCHONDRIAL_ENVELOPE, SCHLOSSER_SERUM_RESPONSE_DN, GOBP_POSITIVE_REGULATION_OF_TRANSPORT, GOBP_REGULATION_OF_TRANSPORT
GO Biological Process (4): mitophagy (GO:0000423), mitochondrion organization (GO:0007005), positive regulation of high voltage-gated calcium channel activity (GO:1901843), autophagy (GO:0006914)
GO Molecular Function (2): protein-macromolecule adaptor activity (GO:0030674), protein binding (GO:0005515)
GO Cellular Component (3): mitochondrion (GO:0005739), mitochondrial outer membrane (GO:0005741), mitochondrial matrix (GO:0005759)
Reactome top-level categories
Rollup of top-1 pathways:
| Category | Pathways |
|---|---|
| RHO GTPase cycle | 2 |
GO top-level categories
Rollup of top GO terms by namespace:
| Category | Terms |
|---|---|
| autophagy of mitochondrion | 1 |
| macroautophagy | 1 |
| organelle organization | 1 |
| high voltage-gated calcium channel activity | 1 |
| positive regulation of voltage-gated calcium channel activity | 1 |
| catabolic process | 1 |
| transmembrane transport | 1 |
| process utilizing autophagic mechanism | 1 |
| protein binding | 1 |
| molecular adaptor activity | 1 |
| binding | 1 |
| cytoplasm | 1 |
| intracellular membrane-bounded organelle | 1 |
| mitochondrial membrane | 1 |
| organelle outer membrane | 1 |
| mitochondrion | 1 |
| intracellular organelle lumen | 1 |
Protein interactions and networks
STRING
1408 interactions, top by confidence (×1000):
| Protein A | Protein B | Partner UniProt | Score |
|---|---|---|---|
| NIPSNAP2 | GABARAPL2 | P60520 | 744 |
| NIPSNAP2 | F5GZY7 | F5GZY7 | 738 |
| NIPSNAP2 | TAX1BP1 | Q86VP1 | 665 |
| NIPSNAP2 | CALCOCO2 | Q13137 | 663 |
| NIPSNAP2 | NBR1 | Q14596 | 647 |
| NIPSNAP2 | FUNDC1 | Q8IVP5 | 595 |
| NIPSNAP2 | BNIP3L | O60238 | 589 |
| NIPSNAP2 | GABARAP | O95166 | 585 |
| NIPSNAP2 | SQSTM1 | Q13501 | 579 |
| NIPSNAP2 | ZNF713 | Q8N859 | 573 |
| NIPSNAP2 | SUMF2 | Q8NBJ7 | 562 |
| NIPSNAP2 | ALDH16A1 | Q8IZ83 | 561 |
| NIPSNAP2 | PINK1 | Q9BXM7 | 550 |
| NIPSNAP2 | EGFR | P00533 | 534 |
| NIPSNAP2 | BNIP3 | Q12983 | 521 |
IntAct
97 interactions, top by confidence:
| A | B | Type | Score |
|---|---|---|---|
| PRKCZ | NIPSNAP2 | psi-mi:“MI:0914”(association) | 0.730 |
| CFTR | ESYT2 | psi-mi:“MI:2364”(proximity) | 0.710 |
| NIPSNAP2 | GABARAPL2 | psi-mi:“MI:0407”(direct interaction) | 0.700 |
| GABARAPL2 | NIPSNAP2 | psi-mi:“MI:0915”(physical association) | 0.700 |
| GABARAPL2 | IPO5 | psi-mi:“MI:0914”(association) | 0.690 |
| KLHL22 | TMEM223 | psi-mi:“MI:0914”(association) | 0.640 |
| NIPSNAP2 | HSPD1 | psi-mi:“MI:0914”(association) | 0.610 |
| NIPSNAP2 | GABARAPL1 | psi-mi:“MI:0407”(direct interaction) | 0.590 |
| GABARAPL1 | NIPSNAP2 | psi-mi:“MI:0915”(physical association) | 0.590 |
| GABARAPL1 | IPO5 | psi-mi:“MI:0914”(association) | 0.590 |
| GABARAP | IPO5 | psi-mi:“MI:0914”(association) | 0.590 |
| NIPSNAP2 | MAP1LC3C | psi-mi:“MI:0407”(direct interaction) | 0.540 |
| MAP1LC3C | NIPSNAP2 | psi-mi:“MI:0915”(physical association) | 0.540 |
| PRKCI | NIPSNAP2 | psi-mi:“MI:0914”(association) | 0.530 |
| PRKCZ | IPO5 | psi-mi:“MI:0914”(association) | 0.530 |
| EBNA-LP | HAX1 | psi-mi:“MI:0914”(association) | 0.530 |
| NIPSNAP2 | GABARAP | psi-mi:“MI:0407”(direct interaction) | 0.520 |
| NIPSNAP2 | MAP1LC3B | psi-mi:“MI:0407”(direct interaction) | 0.520 |
| MAP1LC3B | NIPSNAP2 | psi-mi:“MI:0914”(association) | 0.520 |
| CDH1 | ACTN4 | psi-mi:“MI:0914”(association) | 0.500 |
| PYROXD1 | NIPSNAP2 | psi-mi:“MI:0915”(physical association) | 0.400 |
| Prkci | LLGL2 | psi-mi:“MI:0914”(association) | 0.350 |
| JUN | TPM3 | psi-mi:“MI:0914”(association) | 0.350 |
| Xpo1 | IFT56 | psi-mi:“MI:0914”(association) | 0.350 |
BioGRID (307): GBAS (Affinity Capture-RNA), GBAS (Affinity Capture-RNA), GBAS (Affinity Capture-MS), GBAS (Affinity Capture-MS), GBAS (Affinity Capture-MS), GBAS (Affinity Capture-MS), GBAS (Proximity Label-MS), GBAS (Proximity Label-MS), GBAS (Affinity Capture-MS), HSPD1 (Affinity Capture-MS), NIPSNAP1 (Affinity Capture-MS), WBP11 (Affinity Capture-MS), SF3B5 (Affinity Capture-MS), GBAS (Affinity Capture-MS), GBAS (Affinity Capture-MS)
ESM2 similar proteins: A0A063C1W0, A0A2I1C3W7, A0A5B8YU67, A2BGU9, B3P9N0, B4I9J6, B4PY69, B4R313, B8DH02, B9DKR5, B9FK36, C1KX66, E1ACR2, F4I1L3, F6NVH9, I1RVD6, O46084, O55125, O55126, O75323, P27680, P34492, P91929, Q09422, Q16KN5, Q19000, Q29JQ0, Q4WAZ2, Q502L2, Q54I58, Q562B5, Q5FWM4, Q61CA3, Q6C3P4, Q71XQ0, Q8BX10, Q8IQ70, Q8S6N5, Q8SYD0, Q8Y5F1
Diamond homologs: F6NVH9, O55125, O55126, O75323, P34492, Q9BPW8, Q9PU58, Q9VXK0, A6NDG6, D3ZDK7, P0DKC3, P0DKC4, P19881, P60487, Q00472, Q2T9S4, Q3ZBF9, Q5F4B1, Q6ZT62, Q8CHP8, Q8GWU0, Q8VD52, Q96GD0
SIGNOR signaling
0 interactions.
Enriched among interaction partners
Reactome pathways and GO biological processes over-represented among this gene’s 88 IntAct physical interaction partners (hypergeometric vs the genome-wide background, BH-FDR, gene-set size 15–500, ranked by fold). A functional readout of the neighbourhood — distinct from this gene’s own memberships above, and biased toward well-studied / hub proteins, so read it as themes rather than proof.
Reactome pathways:
| Pathway | Partners | Fold | FDR |
|---|---|---|---|
| Macroautophagy | 8 | 15.4× | 2e-05 |
| Autophagy | 5 | 12.4× | 5e-03 |
| KEAP1-NFE2L2 pathway | 5 | 10.0× | 9e-03 |
GO biological processes:
| GO term | Partners | Fold | FDR |
|---|---|---|---|
| mitophagy | 8 | 33.0× | 4e-08 |
| autophagosome maturation | 7 | 31.9× | 5e-07 |
| autophagosome assembly | 7 | 20.4× | 1e-05 |
| macroautophagy | 5 | 15.6× | 2e-03 |
Disease & clinical
Clinical variants and AI predictions
ClinVar
70 variants total. Per-class counts are floors (≥ shown; pagination cap):
| Classification | Count (floor) |
|---|---|
| Pathogenic | 0 |
| Likely pathogenic | 0 |
| Uncertain significance | 50 |
| Likely benign | 1 |
| Benign | 0 |
Top pathogenic / likely-pathogenic (0)
SpliceAI
2367 predictions. Top by Δscore:
| Variant | Effect | Δscore |
|---|---|---|
| 7:55951929:AG:A | donor_loss | 1.0000 |
| 7:55951932:T:A | donor_loss | 1.0000 |
| 7:55953173:TTTCA:T | acceptor_loss | 1.0000 |
| 7:55953174:TTCA:T | acceptor_loss | 1.0000 |
| 7:55953174:TTCAG:T | acceptor_loss | 1.0000 |
| 7:55953175:TCAGG:T | acceptor_loss | 1.0000 |
| 7:55953176:CAGGT:C | acceptor_loss | 1.0000 |
| 7:55953177:AGGTG:A | acceptor_loss | 1.0000 |
| 7:55953178:G:T | acceptor_loss | 1.0000 |
| 7:55953315:AAAG:A | donor_loss | 1.0000 |
| 7:55953316:AAGG:A | donor_loss | 1.0000 |
| 7:55953319:GT:G | donor_loss | 1.0000 |
| 7:55953320:T:G | donor_loss | 1.0000 |
| 7:55954905:ACAG:A | acceptor_loss | 1.0000 |
| 7:55954906:CAGT:C | acceptor_loss | 1.0000 |
| 7:55954907:A:AG | acceptor_gain | 1.0000 |
| 7:55954907:A:T | acceptor_loss | 1.0000 |
| 7:55954908:G:GC | acceptor_gain | 1.0000 |
| 7:55954908:G:GG | acceptor_gain | 1.0000 |
| 7:55954908:G:T | acceptor_loss | 1.0000 |
| 7:55954908:GT:G | acceptor_gain | 1.0000 |
| 7:55954908:GTA:G | acceptor_gain | 1.0000 |
| 7:55954908:GTATT:G | acceptor_gain | 1.0000 |
| 7:55978264:GT:G | donor_gain | 1.0000 |
| 7:55978266:G:GG | donor_gain | 1.0000 |
| 7:55981622:T:G | donor_gain | 1.0000 |
| 7:55982203:A:AG | acceptor_gain | 1.0000 |
| 7:55982209:G:GA | acceptor_gain | 1.0000 |
| 7:55997364:A:G | acceptor_gain | 1.0000 |
| 7:55951927:GGAG:G | donor_gain | 0.9900 |
AlphaMissense
1876 scored. Top likely-pathogenic:
| Variant | Protein change | am_pathogenicity |
|---|---|---|
| 7:55978359:T:A | V81D | 1.000 |
| 7:55981528:G:T | G112W | 1.000 |
| 7:55981529:G:A | G112E | 1.000 |
| 7:55981534:T:A | W114R | 1.000 |
| 7:55981534:T:C | W114R | 1.000 |
| 7:55981562:A:C | Q123P | 1.000 |
| 7:55982210:T:A | V125D | 1.000 |
| 7:55982216:T:C | L127P | 1.000 |
| 7:55982218:T:A | W128R | 1.000 |
| 7:55982218:T:C | W128R | 1.000 |
| 7:55983797:T:C | F172L | 1.000 |
| 7:55983798:T:C | F172S | 1.000 |
| 7:55983799:C:A | F172L | 1.000 |
| 7:55983799:C:G | F172L | 1.000 |
| 7:55983806:T:A | W175R | 1.000 |
| 7:55983806:T:C | W175R | 1.000 |
| 7:55983849:T:C | L189P | 1.000 |
| 7:55983852:G:T | R190M | 1.000 |
| 7:55983864:T:A | L194H | 1.000 |
| 7:55983864:T:C | L194P | 1.000 |
| 7:55984851:G:A | G197E | 1.000 |
| 7:55984865:T:A | W202R | 1.000 |
| 7:55984865:T:C | W202R | 1.000 |
| 7:55984867:G:C | W202C | 1.000 |
| 7:55984867:G:T | W202C | 1.000 |
| 7:55984877:T:A | W206R | 1.000 |
| 7:55984877:T:C | W206R | 1.000 |
| 7:55994914:G:C | R213T | 1.000 |
| 7:55994941:G:A | G222E | 1.000 |
| 7:55994958:G:T | G228W | 1.000 |
dbSNP variants (sampled 300 via entrez): RS1000064561 (7:55979511 G>A), RS1000083167 (7:55997225 T>C), RS1000116580 (7:55979881 A>C,G), RS1000144739 (7:55999561 T>C,G), RS1000175011 (7:55963324 C>G), RS1000226653 (7:55973464 T>G), RS1000303189 (7:55968586 C>G,T), RS1000333956 (7:55968340 G>A), RS1000512050 (7:55964506 C>A,T), RS1000598526 (7:55973717 C>T), RS1000621434 (7:55999873 A>G), RS1000652911 (7:55995568 G>A), RS1000728743 (7:55990109 C>T), RS1000761643 (7:55989786 T>G), RS1000862356 (7:55988829 CA>C)
Disease associations
OMIM: gene MIM:603004 | disease phenotypes:
GenCC curated gene-disease
Mondo (0):
Orphanet (0):
HPO phenotypes
0 total (0 of 0 shown, HPO-id order):
GWAS associations
10 associations (top):
| Study | Trait | p-value |
|---|---|---|
| GCST006868_5 | Type 2 diabetes | 2.000000e-08 |
| GCST007382_29 | Plasma free amino acid levels (adjusted for twenty other PFAAs) | 5.000000e-22 |
| GCST007385_17 | Plasma free amino acid levels | 4.000000e-21 |
| GCST007876_103 | Estimated glomerular filtration rate | 1.000000e-08 |
| GCST011352_27 | Alanine aminotransferase levels | 3.000000e-08 |
| GCST012251_16 | Macular telangiectasia type 2 | 3.000000e-07 |
| GCST012252_7 | Macular telangiectasia type 2 | 6.000000e-09 |
| GCST90002388_390 | Lymphocyte count | 1.000000e-15 |
| GCST90002407_479 | White blood cell count | 9.000000e-12 |
| GCST90013405_7 | Liver enzyme levels (alanine transaminase) | 4.000000e-10 |
EFO canonical traits (4, from GWAS)
| EFO ID | Trait name |
|---|---|
| EFO:0005134 | amino acid measurement |
| EFO:0009774 | serine measurement |
| EFO:1002009 | macular telangiectasia type 2 |
| EFO:0004587 | lymphocyte count |
Drugs & pharmacology
Drug and pharmacology data
Is drug target: no
PharmGKB: 1 entry (VIP=true, CPIC=false)
CTD chemical–gene interactions
35 total (human), top 30 by PubMed support.
| Chemical | Actions (top 5) | PubMed papers |
|---|---|---|
| Valproic Acid | affects expression, decreases expression | 6 |
| sodium arsenite | decreases expression, affects cotreatment, increases abundance | 3 |
| cobaltous chloride | decreases expression | 2 |
| Cyclosporine | decreases expression | 2 |
| Cadmium Chloride | increases expression, decreases expression | 2 |
| aristolochic acid I | decreases expression | 1 |
| dicrotophos | decreases expression | 1 |
| pirinixic acid | increases activity, affects binding, decreases expression | 1 |
| manganese chloride | increases abundance, affects cotreatment, decreases expression | 1 |
| periodate-oxidized adenosine | affects expression | 1 |
| aflatoxin B2 | increases methylation | 1 |
| di-n-butylphosphoric acid | affects expression | 1 |
| perfluorooctane sulfonic acid | decreases expression | 1 |
| ICG 001 | decreases expression | 1 |
| abrine | decreases expression | 1 |
| bisphenol AF | increases expression | 1 |
| Temozolomide | increases expression | 1 |
| Arsenic | increases abundance, affects cotreatment, decreases expression | 1 |
| Benzo(a)pyrene | increases methylation | 1 |
| Cadmium | decreases expression | 1 |
| Dimethyl Sulfoxide | increases expression | 1 |
| Doxorubicin | decreases expression | 1 |
| Ethyl Methanesulfonate | decreases expression | 1 |
| Fluorouracil | affects reaction, decreases expression | 1 |
| Formaldehyde | decreases expression | 1 |
| Ivermectin | decreases expression | 1 |
| Manganese | increases abundance, affects cotreatment, decreases expression | 1 |
| Methyl Methanesulfonate | decreases expression | 1 |
| Sodium Dodecyl Sulfate | decreases expression | 1 |
| Thiram | decreases expression | 1 |
Clinical trials (associated diseases)
0 trials via MONDO — disease-level, not drug-specific.
Related Atlas pages
No linked Atlas pages yet — the cross-entity mesh grows as the corpus expands.